Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$8.0 million.

  • Ascendis Pharma A's Tax Provisions fell 58849.35% to -$8.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$17.7 million, marking a year-over-year decrease of 23676.45%. This contributed to the annual value of -$17.4 million for FY2025, which is 23591.63% down from last year.
  • Ascendis Pharma A's Tax Provisions amounted to -$8.0 million in Q4 2025, which was down 58849.35% from -$4.2 million recorded in Q3 2025.
  • Ascendis Pharma A's Tax Provisions' 5-year high stood at $1.4 million during Q1 2023, with a 5-year trough of -$8.0 million in Q4 2025.
  • For the 5-year period, Ascendis Pharma A's Tax Provisions averaged around -$1.7 million, with its median value being -$486312.1 (2022).
  • The largest annual percentage gain for Ascendis Pharma A's Tax Provisions in the last 5 years was 227971.14% (2022), contrasted with its biggest fall of 408385.81% (2022).
  • Quarter analysis of 5 years shows Ascendis Pharma A's Tax Provisions stood at -$130412.7 in 2021, then crashed by 4083.86% to -$5.5 million in 2022, then decreased by 14.19% to -$6.2 million in 2023, then skyrocketed by 81.39% to -$1.2 million in 2024, then plummeted by 588.49% to -$8.0 million in 2025.
  • Its Tax Provisions was -$8.0 million in Q4 2025, compared to -$4.2 million in Q3 2025 and -$4.4 million in Q2 2025.